

Supplementary material

Pyrazole and Triazole derivatives as Mycobacterium tuberculosis UDP-galactopyranose inhibitors

Dalia M. Ahmed^{1,2}, Jeffrey M. Chen^{3,4,5}, David A. R. Sanders^{1*}

¹ Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9, dalia.ahmed@usask.ca



² Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Egypt


³ Vaccine and Infectious Disease Organization, Saskatoon, Saskatchewan S7N 5E3, Canada, jeffrey.chen@usask.ca

⁴ Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5B4, Canada.



⁵ Vaccinology and Immunotherapeutics Program, School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan S7N 2Z4, Canada.


* Correspondence: david.sanders@usask.ca









DA5







DA6














DA8















DA11





DA12





DA13

